

# Wafik S El-Deiry

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6978231/wafik-s-el-deiry-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

387  
papers

37,614  
citations

86  
h-index

189  
g-index

551  
ext. papers

42,378  
ext. citations

7.8  
avg, IF

7.35  
L-index

#	Paper	IF	Citations
387	Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	4
386	BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 128-128 <sup>2.2</sup>		0
385	Colorectal cancer extracellular acidosis decreases immune cell killing and is partially ameliorated by pH-modulating agents that modify tumor cell cytokine profiles.. <i>American Journal of Cancer Research</i> , <b>2022</b> , 12, 138-151	4.4	
384	miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.. <i>American Journal of Cancer Research</i> , <b>2022</b> , 12, 315-326	4.4	
383	Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).. <i>American Journal of Cancer Research</i> , <b>2022</b> , 12, 729-743	4.4	
382	Integrin/TGF- $\beta$ Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 618	5.2	0
381	Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 747895	5.6	0
380	Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 747194	5.6	3
379	Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 1107-1123	4.4	1
378	Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 751568	5.6	1
377	Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. <i>Cancer Biology and Therapy</i> , <b>2021</b> , 1-12	4.6	0
376	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , <b>2021</b> , 12, 2423-2437	2.8	1
375	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 95	9.8	1
374	Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1 $\beta$ proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90. <i>Scientific Reports</i> , <b>2021</b> , 11, 20871	4.9	2
373	Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer and. <i>Cancer Biology and Therapy</i> , <b>2021</b> , 1-10	4.6	1
372	Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 68-73	2.7	2
371	P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9. <i>Neoplasia</i> , <b>2021</b> , 23, 304-325	6.4	5

370	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
369	Strategies to sensitize cancer cells to immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 17, 2595-2601	4.4	5
368	The Role of BCL-2 Proteins in the Development of Castration-resistant Prostate Cancer and Emerging Therapeutic Strategies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 374-382	2.7	2
367	ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 1572-1583	6.1	3
366	A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
365	First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, e43-e52	3.8	3
364	The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 183-190	6.1	2
363	Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. <i>Oncotarget</i> , <b>2021</b> , 12, 2131-2148	3.3	1
362	Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2021</b> , 1876, 188556	11.2	28
361	Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 747180	5.6	3
360	EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. <i>Neoplasia</i> , <b>2021</b> , 23, 792-810	6.4	11
359	A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs. <i>Oncotarget</i> , <b>2021</b> , 12, 1980-1991	3.3	2
358	Targeting the Integrated Stress Response in Cancer Therapy. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 747837	5.6	12
357	Identification of Smurf2 as a HIF-1 $\alpha$ -degrading E3 ubiquitin ligase. <i>Oncotarget</i> , <b>2021</b> , 12, 1970-1979	3.3	2
356	Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients. <i>Oncotarget</i> , <b>2021</b> , 12, 1992-2005	3.3	4
355	Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 1761-1773	5.1	1
354	Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells. <i>Oncotarget</i> , <b>2021</b> , 12, 2006-2021	3.3	2
353	Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19 <b>2021</b> ,		3

352	Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2. <i>ELife</i> , <b>2021</b> , 10,	8.9	8
351	CDKN1A/p21, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 5452-5471	4.4	2
350	Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 6086-6106	4.4	1
349	ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. <i>Neoplasia</i> , <b>2020</b> , 22, 725-744	6.4	36
348	Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3K $\beta$ isoform. <i>Communications Biology</i> , <b>2020</b> , 3, 267	6.7	8
347	Targeting apoptosis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 395-417	19.4	389
346	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. <i>Oncotarget</i> , <b>2020</b> , 11, 3753-3769	3.3	8
345	MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. <i>Oncotarget</i> , <b>2020</b> , 11, 4201-4223	3.3	13
344	DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , <b>2020</b> , 22, iii299-iii299	1	0
343	Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells <b>2020</b> ,		6
342	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. <i>Cell Death Discovery</i> , <b>2020</b> , 6, 57	6.9	18
341	Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARS CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 595289	8.4	2
340	Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 1416-1419	5.7	19
339	Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration <b>2019</b> , 7, 136		29
338	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2019</b> , 69, 305-343	220.7	86
337	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. <i>Leukemia</i> , <b>2019</b> , 33, 2429-2441	10.7	10
336	Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 142	5.3	3
335	Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 1389-1397	4.6	3

334	A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15020-e15020	2.2	
333	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2305-2313	12.9	27
332	Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 652	5.3	8
331	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 731-739	59.2	1285
330	Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. <i>Neoplasia</i> , <b>2018</b> , 20, 244-255	6.4	11
329	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 486-541	12.7	2160
328	Bcl-2 Protein Targeting by the p53/p21 Complex-Letter. <i>Cancer Research</i> , <b>2018</b> , 78, 2770-2771	10.1	4
327	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 754-766	6.6	15
326	CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. <i>Cell Cycle</i> , <b>2018</b> , 17, 557-567	4.7	7
325	From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2018</b> , 631-646	0.4	1
324	Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 11	12.8	13
323	TRAIL pathway targeting therapeutics. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2018</b> , 3, 197-204	1.6	11
322	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2325-2338	15.9	38
321	Role of Dopamine Receptors in the Anticancer Activity of ONC201. <i>Neoplasia</i> , <b>2018</b> , 20, 80-91	6.4	57
320	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. <i>Cell Cycle</i> , <b>2018</b> , 17, 468-478	4.7	19
319	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1341-1367	2.2	75
318	Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice. <i>Cancer Research</i> , <b>2017</b> , 77, 1250-1260	10.1	45
317	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1290-1298	6.1	27

316	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. <i>Cell Cycle</i> , <b>2017</b> , 16, 1790-1799	4.7	36
315	Impact of perineural invasion on survival in node negative colon cancer. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 740-745	4.6	9
314	Tissue TGF- $\beta$ expression following conventional radiotherapy and pulsed low-dose-rate radiation. <i>Cell Cycle</i> , <b>2017</b> , 16, 1171-1174	4.7	11
313	The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. <i>Cell Cycle</i> , <b>2017</b> , 16, 1193-1200	4.7	26
312	First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4163-4169	12.9	77
311	miR-6883 Family miRNAs Target CDK4/6 to Induce G Phase Cell-Cycle Arrest in Colon Cancer Cells. <i>Cancer Research</i> , <b>2017</b> , 77, 6902-6913	10.1	34
310	BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 39945-39962	3.3	17
309	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. <i>Oncotarget</i> , <b>2017</b> , 8, 86356-86368	3.3	102
308	Circulating tumor cells: silent predictors of metastasis. <i>F1000Research</i> , <b>2017</b> , 6,	3.6	30
307	Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. <i>Oncotarget</i> , <b>2017</b> , 8, 66747-66757	3.3	55
306	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, e8-e15	7.1	9
305	Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 694-704	4.6	7
304	P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. <i>Scientific Reports</i> , <b>2017</b> , 7, 9711	4.9	15
303	Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 651-654	4.6	5
302	Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth. <i>Cell Cycle</i> , <b>2017</b> , 16, 1719-1725	4.7	5
301	Targeting Oncoproteins for Molecular Cancer Therapy <b>2017</b> , 727-756		
300	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <i>Oncotarget</i> , <b>2017</b> , 8, 29887-29905	3.3	8
299	Abstract 2792: The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway <b>2017</b> ,		3

298	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. <i>PLoS ONE</i> , <b>2017</b> , 12, e0180541	3.7	22
297	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. <i>Oncotarget</i> , <b>2017</b> , 8, 81776-81793	3.3	26
296	ONC201: a new treatment option being tested clinically for recurrent glioblastoma. <i>Translational Cancer Research</i> , <b>2017</b> , 6, S1239-S1243	0.3	15
295	Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2017</b> , 1-25	0.3	1
294	p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy. <i>Cancer Research</i> , <b>2016</b> , 76, 5189-91	10.1	143
293	Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 6192-6203	12.9	27
292	The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 5960-5970	5.4	19
291	Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated p73 Inhibition and p73 Activation. <i>Cancer Research</i> , <b>2016</b> , 76, 1989-99	10.1	43
290	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
289	ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2 $\alpha$ kinases. <i>Science Signaling</i> , <b>2016</b> , 9, ra18	8.8	114
288	Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity. <i>Cancer Research</i> , <b>2016</b> , 76, 700-712	10.1	10
287	Discovery and clinical introduction of first-in-class imipridone ONC201. <i>Oncotarget</i> , <b>2016</b> , 7, 74380-74393	3.3	83
286	A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. <i>Oncotarget</i> , <b>2016</b> , 7, 3662-76	3.3	23
285	Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. <i>Current Colorectal Cancer Reports</i> , <b>2016</b> , 12, 151-161	1	42
284	Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. <i>Cancer Research</i> , <b>2015</b> , 75, 1423-32	10.1	92
283	Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1136-9	4.6	
282	Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 709-13	4.6	18
281	Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 699-708	4.6	42

280	Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 690-8	4.6	19
279	Acoustic separation of circulating tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 4970-5	11.5	497
278	A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 377-82	4.6	4
277	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. <i>Cancer Research</i> , <b>2015</b> , 75, 3842-52 <sup>10.1</sup>	10.1	67
276	Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1726-37	4.6	58
275	Colon Stem Cells in Colorectal Cancer <b>2015</b> , 169-192		1
274	Targeting TRAIL in the treatment of cancer: new developments. <i>Expert Opinion on Therapeutic Targets</i> , <b>2015</b> , 19, 1171-85	6.4	77
273	ONC201 induces cell death in pediatric non-HodgkinB lymphoma cells. <i>Cell Cycle</i> , <b>2015</b> , 14, 2422-8	4.7	23
272	Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. <i>Molecular Cancer</i> , <b>2015</b> , 14, 99	42.1	47
271	Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. <i>Cancer Research</i> , <b>2015</b> , 75, 1668-74	10.1	35
270	Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1710-9	4.6	14
269	TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1156-63	13.4	73
268	A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 835-43	6.1	11
267	Therapeutic biomarker differences between MSI-H and MSS colorectal cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3597-3597	2.2	1
266	Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type microsatellite instable (MSI-H) colorectal cancer (CRC) and association of wnt pathway corepressor TLE-3.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3611-3611	2.2	1
265	First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143082	3.7	29
264	Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. <i>Oncotarget</i> , <b>2015</b> , 6, 3784-96	3.3	14
263	Novel and Emerging Targeted Therapies of Colorectal Cancer. <i>Current Clinical Pharmacology</i> , <b>2015</b> , 10, 279-98	2.5	5



262	Association of increase in BRCA2 gene mutations in microsatellite instable (MSI-H) colorectal cancer (CRC) with increased c-MET expression.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14684-e14684	2.2	
261	Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. <i>Cancer Research</i> , <b>2014</b> , 74, 1153-65	10.1	48
260	COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. <i>Cancer Research</i> , <b>2014</b> , 74, 2385-90	10.1	12
259	Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. <i>Clinical Chemistry</i> , <b>2014</b> , 60, 323-33	5.5	103
258	Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, 119-26	3.8	23
257	The NFB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 602-11	4.6	13
256	Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 443-51	4.6	17
255	Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report. <i>Oncology Letters</i> , <b>2014</b> , 7, 2110-2112	2.6	2
254	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 2626-39	15.9	209
253	ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. <i>Blood</i> , <b>2014</b> , 124, 5219-5219	2.2	2
252	Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. <i>Oncotarget</i> , <b>2014</b> , 5, 1753-60	3.3	23
251	The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. <i>Oncotarget</i> , <b>2014</b> , 5, 12728-37	3.3	33
250	HIF-1 signaling in drug resistance to chemotherapy. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 3021-8	4.3	81
249	Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. <i>Current Drug Targets</i> , <b>2014</b> , 15, 80-9	3	158
248	Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , <b>2014</b> , 124, 5233-5233	2.2	
247	Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins. <i>Blood</i> , <b>2014</b> , 124, 5237-5237	2.2	1
246	Impact of genetic targets on cancer therapy. Forward. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> , 779, v-vi	3.6	1
245	Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 171ra17	17.5	188

244	Novel antineoplastics targeting genetic changes in colorectal cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> , 779, 1-34	3.6	5
243	CDK1 stabilizes HIF-1 via direct phosphorylation of Ser668 to promote tumor growth. <i>Cell Cycle</i> , <b>2013</b> , 12, 3689-701	4.7	64
242	Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. <i>Cell Cycle</i> , <b>2013</b> , 12, 2132-43	4.7	22
241	Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. <i>Pharmaceuticals</i> , <b>2013</b> , 6, 988-1038	5.2	12
240	Detection of DSS-induced gastrointestinal mucositis in mice by non-invasive optical near-infrared (NIR) imaging of cathepsin activity. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 736-41	4.6	5
239	p21WAF1 and tumorigenesis: 20 years after. <i>Current Opinion in Oncology</i> , <b>2013</b> , 25, 52-8	4.2	221
238	Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 699-702	4.6	4
237	Welcoming Paul Dent as Assistant Editor-in-Chief of Cancer Biology & Therapy. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 773-773	4.6	78
236	Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 1174-81	4.6	13
235	The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo. <i>Cell Cycle</i> , <b>2013</b> , 12, 2241-2247	4.7	3
234	FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 711-9	4.6	10
233	REDOX IMAGING OF THE p53-DEPENDENT MITOCHONDRIAL REDOX STATE IN COLON CANCER. <i>Journal of Innovative Optical Health Sciences</i> , <b>2013</b> , 6,	1.2	13
232	Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 703-10	4.6	28
231	Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. <i>PLoS ONE</i> , <b>2013</b> , 8, e75414	3.7	34
230	The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e59380	3.9	10
229	Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on Ecatenin. <i>Oncotarget</i> , <b>2013</b> , 4, 184-91	3.3	7
228	Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2087-95	6.1	22
227	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , <b>2012</b> , 8, 445-544	4.2	2783

226	Therapeutic targeting of the p53 pathway in cancer stem cells. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16, 1161-74	6.4	29
225	Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. <i>Cell Cycle</i> , <b>2012</b> , 11, 3312-23	4.7	23
224	Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. <i>Oncology Reports</i> , <b>2012</b> , 28, 883-8	3.5	1
223	Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. <i>Oncolmmunology</i> , <b>2012</b> , 1, 1507-1516	7.2	6
222	Regulation of the human TRAIL gene. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 1143-51	4.6	66
221	An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. <i>Biomicrofluidics</i> , <b>2012</b> , 6, 24113-241139	3.2	88
220	Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2321-30	6.1	10
219	Compartmentalization of tumor cells to the CSF or peripheral blood of a breast cancer patient with CNS metastasis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e11544-e11544	2.2	
218	Utility of dual-modality bioluminescence and MRI in monitoring stem cell survival and impact on post myocardial infarct remodeling. <i>Academic Radiology</i> , <b>2011</b> , 18, 3-12	4.3	17
217	High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 2169-76	5.8	2
216	Death receptor 5 signaling promotes hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 39336-48	5.4	93
215	Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. <i>Oncotarget</i> , <b>2011</b> , 2, 752-60	3.3	68
214	The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. <i>Cell Cycle</i> , <b>2011</b> , 10, 2380-9	4.7	54
213	FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. <i>International Journal of Oncology</i> , <b>2011</b> , 39, 91-100	4.4	3
212	Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 335-48	4.6	10
211	Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3 $\beta$ and CDK1. <i>Cancer Research</i> , <b>2011</b> , 71, 5265-75	10.1	27
210	Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 86ra50	17.5	35
209	Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 239-51	4.6	36

208	Spectral imaging-based methods for quantifying autophagy and apoptosis. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 349-56	4.6	14
207	Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 229-38	4.6	43
206	Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 326-34	4.6	5
205	Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 557-68	4.6	16
204	Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. <i>Cell Cycle</i> , <b>2011</b> , 10, 2331-8	4.7	49
203	The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. <i>Cancer Research</i> , <b>2010</b> , 70, 8233-46	10.1	218
202	TRAIL receptor signaling and therapeutics. <i>Expert Opinion on Therapeutic Targets</i> , <b>2010</b> , 14, 1091-108	6.4	123
201	Circulating Tumor Cells and Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2010</b> , 6, 212-220	1	46
200	Current strategies to target p53 in cancer. <i>Biochemical Pharmacology</i> , <b>2010</b> , 80, 724-30	6	127
199	Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2194-205	4.6	12
198	Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2406-16	4.6	24
197	The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2186-93	4.6	21
196	The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. <i>Cell Cycle</i> , <b>2009</b> , 8, 4168-75	4.7	56
195	Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2417-44	4.6	12
194	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 3285-95	6.1	30
193	Multispectral fluorescence imaging. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 1563-6	8.9	43
192	Response: CARP1 regulates induction of NF- $\kappa$ B by TNF. <i>Current Biology</i> , <b>2009</b> , 19, R17-R19	6.3	11
191	Targeting p53 for enhanced radio- and chemo-sensitivity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2009</b> , 14, 597-606	5.4	106

190	Cell death: a new Par-4 the TRAIL. <i>Cell</i> , <b>2009</b> , 138, 220-2	56.2	6
189	GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. <i>Molecular Cell</i> , <b>2009</b> , 36, 379-92	17.6	76
188	Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. <i>Radiation Research</i> , <b>2009</b> , 172, 175-86	3.1	42
187	CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. <i>Current Biology</i> , <b>2008</b> , 18, 641-9	6.3	54
186	The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. <i>Gastroenterology</i> , <b>2008</b> , 134, 1981-93	13.3	96
185	Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2901-10	2.2	57
184	Regulation of programmed cell death by the p53 pathway. <i>Advances in Experimental Medicine and Biology</i> , <b>2008</b> , 615, 201-21	3.6	67
183	Mcl-1: a gateway to TRAIL sensitization. <i>Cancer Research</i> , <b>2008</b> , 68, 2062-4	10.1	97
182	Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 2023-33	4.6	48
181	Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 2047-53	4.6	21
180	TRAIL death receptors as tumor suppressors and drug targets. <i>Cell Cycle</i> , <b>2008</b> , 7, 1525-8	4.7	34
179	Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 2039-46	4.6	28
178	CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2. <i>Cell Cycle</i> , <b>2008</b> , 7, 670-82	4.7	26
177	TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. <i>Cancer Research</i> , <b>2008</b> , 68, 3440-9	10.1	38
176	Studying p53-dependent cell death in vitro and in vivo. <i>Methods in Enzymology</i> , <b>2008</b> , 446, 159-73	1.7	5
175	DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. <i>Cancer Research</i> , <b>2008</b> , 68, 909-17	10.1	37
174	Structural and functional basis for therapeutic modulation of p53 signaling. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6376-86	12.9	50
173	TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 2034-8	4.6	65

172	Restoration of p53 to limit tumor growth. <i>Current Opinion in Oncology</i> , <b>2008</b> , 20, 90-6	4.2	87
171	Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing. <i>BioTechniques</i> , <b>2008</b> , 45, 459-60, 461-4	2.5	32
170	TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 111-23	15.9	133
169	p53, BRCA1 and breast Cancer chemoresistance. <i>Advances in Experimental Medicine and Biology</i> , <b>2007</b> , 608, 70-86	3.6	31
168	Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. <i>Cancer Cell</i> , <b>2007</b> , 12, 66-80	24.3	226
167	Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. <i>Cancer Research</i> , <b>2007</b> , 67, 9443-54	10.1	109
166	CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 3273-81	5.4	60
165	P53, Cell Cycle Arrest and Apoptosis <b>2007</b> , 141-163		6
164	Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1490-5	4.6	62
163	Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1649-53	4.6	12
162	Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1858-66	4.6	23
161	Differentiation of vascular and non-vascular skin spectral signatures using in vivo hyperspectral radiometric imaging: implications for monitoring angiogenesis. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 447-53	4.6	5
160	Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. <i>Cell Cycle</i> , <b>2007</b> , 6, 2571-8	4.7	46
159	CARPs are E3 ligases that target apical caspases and p53. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1676-83	4.6	8
158	IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 534-40	4.6	22
157	Hyperspectral image analysis of live cells in various cell cycle stages. <i>Cell Cycle</i> , <b>2007</b> , 6, 2563-70	4.7	9
156	Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. <i>Cell Cycle</i> , <b>2007</b> , 6, 2554-62	4.7	68
155	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. <i>Genes and Development</i> , <b>2007</b> , 21, 2788-803	12.6	141

154	Childhood ALL and second neoplasms. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1525-31	4.6	5
153	Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. <i>American Journal of Pathology</i> , <b>2007</b> , 170, 709-21	5.8	106
152	Targeting mutant p53 shows promise for sunscreens and skin cancer. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 3658-60	15.9	11
151	The Extrinsic Pathway of Apoptosis <b>2007</b> , 31-54		2
150	p53, Cell Cycle Arrest and Apoptosis <b>2007</b> , 141-163		
149	Taming NEMO to slay cancer cells. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1096-7	4.6	2
148	Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1408-14	4.6	31
147	Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1228-35	4.6	23
146	What are caspases 3 and 7 doing upstream of the mitochondria?. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 763-5	4.6	96
145	EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. <i>American Journal of Physiology - Renal Physiology</i> , <b>2006</b> , 290, G404-16	5.1	27
144	p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. <i>Cancer Research</i> , <b>2006</b> , 66, 6982-9	10.1	86
143	Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. <i>Molecular and Cellular Biology</i> , <b>2006</b> , 26, 8136-48	4.8	103
142	Imaging and oncologic drug development. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3261-73	2.2	73
141	Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4132-6	12.9	12
140	Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1033-8	4.6	73
139	Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 11003-8	11.5	113
138	Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. <i>Cancer Research</i> , <b>2006</b> , 66, 10415-24	10.1	36
137	The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2006</b> , 12, 247-9	2.2	3

136	Critical role for Daxx in regulating Mdm2. <i>Nature Cell Biology</i> , <b>2006</b> , 8, 855-62	23.4	183
135	Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1285-94	4.6	93
134	Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 937-42	4.6	9
133	Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1068-74	4.6	17
132	Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1409-14	4.6	23
131	Mammalian Cell Death Pathways <b>2005</b> , 1-41		1
130	Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. <i>Molecular and Cellular Biology</i> , <b>2005</b> , 25, 3364-87	4.8	94
129	p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 3568-74	5.6	48
128	Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 885-92	4.6	49
127	Acridine derivatives activate p53 and induce tumor cell death through Bax. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 893-8	4.6	64
126	Overview of cell death signaling pathways. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 139-63	4.6	860
125	Glucocorticoid-induced tumor necrosis factor receptor is a p21Cip1/WAF1 transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 37725-31	5.4	23
124	DR5 knockout mice are compromised in radiation-induced apoptosis. <i>Molecular and Cellular Biology</i> , <b>2005</b> , 25, 2000-13	4.8	92
123	Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1014-7	4.6	19
122	Transcriptional Activation by p53: Mechanisms and Targeted Genes <b>2005</b> , 53-80		1
121	Zebrafish: swimming towards a role for fanconi genes in DNA repair. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 501-2	4.6	10
120	Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 6170-5	11.5	92
119	Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. <i>Cancer Research</i> , <b>2004</b> , 64, 3126-36	10.1	59



118	Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. <i>Cancer Research</i> , <b>2004</b> , 64, 6666-72	10.1	101
117	Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. <i>Cancer Research</i> , <b>2004</b> , 64, 7711-23	10.1	75
116	Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 8541-55	4.8	208
115	Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 40044-52	5.4	68
114	Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype?. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 614-6	4.6	45
113	Cytochrome c: a crosslink between the mitochondria and the endoplasmic reticulum in calcium-dependent apoptosis. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 44-6	4.6	15
112	p53-dependent induction of serine proteases in irradiated mouse colon. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 1290-7	4.6	6
111	Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 35829-39	5.4	182
110	Crystal structure of a FYVE-type zinc finger domain from the caspase regulator CARP2. <i>Structure</i> , <b>2004</b> , 12, 2257-63	5.2	10
109	Targeting p53 by PTD-mediated transduction. <i>Trends in Biotechnology</i> , <b>2004</b> , 22, 431-4	15.1	17
108	Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. <i>Cancer Cell</i> , <b>2004</b> , 6, 597-609	24.3	180
107	Targeting FOXO kills two birds with one stone. <i>Chemistry and Biology</i> , <b>2004</b> , 11, 16-8		9
106	Cell cycle checkpoint control mechanisms that can be disrupted in cancer. <i>Methods in Molecular Biology</i> , <b>2004</b> , 280, 99-161	1.4	34
105	In vivo imaging of MLC2v-luciferase, a cardiac-specific reporter gene expression in mice. <i>Academic Radiology</i> , <b>2004</b> , 11, 1022-8	4.3	14
104	p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 871-5	4.6	21
103	Apoptosis Signaling in Normal and Cancer Cells <b>2004</b> , 497-521		1
102	The p53 pathway: targets for the development of novel cancer therapeutics. <i>Cancer Treatment and Research</i> , <b>2004</b> , 119, 175-87	3.5	21
101	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 5556-71	4.8	191

100	Regulation of the p53 homolog p73 by adenoviral oncogene E1A. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 18313-20	5.4	22
99	Tumor Suppressor Genes <b>2003</b> ,		1
98	Restoring p53-Dependent Tumor Suppression. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 54-62	4.6	21
97	Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 196-202	4.6	72
96	BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 26333-41	5.4	63
95	Caspase 10 Levels are Increased Following DNA Damage in a p53-Dependent Manner. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 705-710	4.6	27
94	Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 431-43	4.6	53
93	Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 15095-100	11.5	132
92	Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation. <i>Methods in Molecular Biology</i> , <b>2003</b> , 223, 129-33	1.4	5
91	Cell death signaling in malignancy. <i>Cancer Treatment and Research</i> , <b>2003</b> , 115, 319-43	3.5	11
90	Clinical implication of p53 mutation in lung cancer. <i>Molecular Biotechnology</i> , <b>2003</b> , 24, 141-56	3	46
89	Cell surface Death Receptor signaling in normal and cancer cells. <i>Seminars in Cancer Biology</i> , <b>2003</b> , 13, 135-47	12.7	250
88	Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 120, 683-92	4.3	43
87	P53 and radiation responses. <i>Oncogene</i> , <b>2003</b> , 22, 5774-83	9.2	391
86	Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. <i>Oncogene</i> , <b>2003</b> , 22, 8394-402	9.2	29
85	The role of p53 in chemosensitivity and radiosensitivity. <i>Oncogene</i> , <b>2003</b> , 22, 7486-95	9.2	254
84	TRAIL and apoptosis induction by TNF-family death receptors. <i>Oncogene</i> , <b>2003</b> , 22, 8628-33	9.2	663
83	Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. <i>Nature Genetics</i> , <b>2003</b> , 35, 229-37	36.3	62

82	DNA footprinting. <i>Methods in Molecular Biology</i> , <b>2003</b> , 223, 117-27	1.4	1
81	Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 2171-81	4.8	132
80	Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 36435-44	5.4	46
79	Frequent hypermethylation of the 5PCpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. <i>Carcinogenesis</i> , <b>2003</b> , 24, 47-51	4.6	79
78	Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. <i>Cancer Research</i> , <b>2003</b> , 63, 5299-307	10.1	33
77	Restoring p53-dependent tumor suppression. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, S55-63	4.6	36
76	Derangement of growth and differentiation control in oncogenesis. <i>BioEssays</i> , <b>2002</b> , 24, 83-90	4.1	24
75	Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. <i>Oncogene</i> , <b>2002</b> , 21, 2623-33	9.2	85
74	BID regulation by p53 contributes to chemosensitivity. <i>Nature Cell Biology</i> , <b>2002</b> , 4, 842-9	23.4	336
73	Transactivation of repair genes by BRCA1. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 490-1	4.6	35
72	Cancer Gene Therapy with the p53 Tumor Suppressor Gene <b>2002</b> , 299-313		1
71	Cancer Gene Therapy with Tumor Suppressor Genes Involved in Cell-Cycle Control <b>2002</b> , 279-297		
70	Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 48827-33	5.4	12
69	Apoptotic threshold is lowered by p53 transactivation of caspase-6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 9492-7	11.5	132
68	BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 4280-92	4.8	134
67	IGFBP-3 mediates p53-induced apoptosis during serum starvation <b>2002</b> , 21, 327		9
66	Enhanced Sensitivity of G1 Arrested Human Cancer Cells Suggests a Novel Therapeutic Strategy Using a Combination of Simvastatin and TRAIL. <i>Cell Cycle</i> , <b>2002</b> , 1, 79-86	4.7	55
65	Phenomenology and scientific progress. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 436-7	4.6	36

64	BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 177-86	4.6	73
63	Clinical and molecular features of small cell lung cancer. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 105-12	4.6	7
62	Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. <i>Experimental Cell Research</i> , <b>2002</b> , 281, 175-81	4.2	24
61	Defining characteristics of Types I and II apoptotic cells in response to TRAIL. <i>Neoplasia</i> , <b>2002</b> , 4, 551-7	6.4	161
60	The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 47-55	4.6	114
59	IGFBP-3 mediates p53-induced apoptosis during serum starvation. <i>International Journal of Oncology</i> , <b>2002</b> , 21, 327-35	1	19
58	p53 and Its Targets <b>2002</b> , 77-96		
57	Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. <i>Cell Cycle</i> , <b>2002</b> , 1, 82-9	4.7	37
56	The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). <i>Cell Cycle</i> , <b>2002</b> , 1, 90-6	4.7	11
55	Tissue-specific induction of p53 targets in vivo. <i>Cancer Research</i> , <b>2002</b> , 62, 7316-27	10.1	155
54	Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. <i>Oncogene</i> , <b>2001</b> , 20, 4601-12	9.2	120
53	The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 38610-8	5.4	138
52	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. <i>Digestion</i> , <b>2001</b> , 64, 75-80	3.6	55
51	Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 37879-86	5.4	127
50	Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. <i>International Journal of Oncology</i> , <b>2001</b> , 18, 241-7	1	11
49	Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 14939-45	5.4	40
48	p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. <i>Experimental Cell Research</i> , <b>2001</b> , 262, 154-69	4.2	124
47	Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2001</b> , 6, 155-162	2.8	5

46	Checkpoint genes in cancer. <i>Annals of Medicine</i> , <b>2001</b> , 33, 113-22	1.5	50
45	Optical imaging <b>2001</b> , 172-182		
44	KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. <i>Advances in Experimental Medicine and Biology</i> , <b>2000</b> , 465, 143-51	3.6	50
43	Tumor suppressor p53 regulation and function. <i>Frontiers in Bioscience - Landmark</i> , <b>2000</b> , 5, d424-437	2.8	4
42	Repression of BRCA1 through a feedback loop involving p53. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 31869-75	5.4	48
41	BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 2777-85	5.4	162
40	p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 269, 179-90	3.4	86
39	The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. <i>Molecular Therapy</i> , <b>2000</b> , 1, 130-44	11.7	99
38	Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. <i>Oncogene</i> , <b>1999</b> , 18, 2357-65	9.2	104
37	The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. <i>Oncogene</i> , <b>1999</b> , 18, 4153-9	9.2	139
36	Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. <i>Oncogene</i> , <b>1999</b> , 18, 6411-8	9.2	93
35	BRCA1 signals ARF-dependent stabilization and coactivation of p53. <i>Oncogene</i> , <b>1999</b> , 18, 6605-14	9.2	62
34	The p53 pathway and apoptosis. <i>Journal of Cellular Physiology</i> , <b>1999</b> , 181, 231-9	7	164
33	The TRAIL to an anti-cancer agent. <i>Drug Resistance Updates</i> , <b>1999</b> , 2, 79-80	23.2	5
32	Transcriptional activation of the cyclin-dependent kinase inhibitor p21 by PML/RARalpha. <i>Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 1, 125-31		4
31	Comparative gene expression profiling in response to p53 in a human lung cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 264, 891-5	3.4	6
30	Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). <i>Molecular and Cellular Biology</i> , <b>1999</b> , 19, 3916-28	4.8	114
29	The Role of p53 in Chemosensitivity <b>1999</b> , 37-52		

28	Regulation of p53 downstream genes. <i>Seminars in Cancer Biology</i> , <b>1998</b> , 8, 345-57	12.7	675
27	Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. <i>Oncogene</i> , <b>1998</b> , 16, 2177-83	9.2	189
26	BRCA1 physically associates with p53 and stimulates its transcriptional activity. <i>Oncogene</i> , <b>1998</b> , 16, 1713-21	9.2	372
25	Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. <i>International Journal of Cancer</i> , <b>1998</b> , 75, 933-40	7.5	47
24	Tumor suppressor gene therapy for cancer: from the bench to the clinic. <i>Drug Resistance Updates</i> , <b>1998</b> , 1, 205-10	23.2	2
23	Identification of a novel AP-2 consensus DNA binding site. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 243, 307-16	3.4	16
22	FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. <i>Science</i> , <b>1998</b> , 279, 1954-8	33.3	805
21	The Gfi-1B proto-oncoprotein represses p21WAF1 and inhibits myeloid cell differentiation. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 2462-73	4.8	105
20	Role of oncogenes in resistance and killing by cancer therapeutic agents. <i>Current Opinion in Oncology</i> , <b>1997</b> , 9, 79-87	4.2	128
19	Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. <i>Oncogene</i> , <b>1997</b> , 14, 1047-57	9.2	155
18	AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. <i>Nature Genetics</i> , <b>1997</b> , 15, 78-82	6.3	265
17	KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. <i>Nature Genetics</i> , <b>1997</b> , 17, 141-3	36.3	927
16	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. <i>Nature</i> , <b>1997</b> , 389, 187-90	50.4	473
15	p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. <i>Experimental Cell Research</i> , <b>1996</b> , 227, 171-81	4.2	114
14	Proteasome-dependent regulation of p21WAF1/CIP1 expression. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 227, 564-9	3.4	212
13	The WAF1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients. <i>Human Pathology</i> , <b>1996</b> , 27, 324-9	3.7	9
12	In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. <i>International Journal of Cancer</i> , <b>1996</b> , 67, 386-92	7.5	171
11	p53 and chemosensitivity. <i>Nature Medicine</i> , <b>1996</b> , 2, 255-6	50.5	65

10	In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug <b>1996</b> , 67, 386		1
9	Polymerase delta variants in RER colorectal tumours. <i>Nature Genetics</i> , <b>1995</b> , 9, 10-1	36.3	120
8	Isolation and characterization of the cDNA encoding human DNA methyltransferase. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 2287-91	20.1	214
7	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. <i>Cell</i> , <b>1992</b> , 71, 587-97	56.2	2767
6	Definition of a consensus binding site for p53. <i>Nature Genetics</i> , <b>1992</b> , 1, 45-9	36.3	1782
5	Mechanisms of error discrimination by Escherichia coli DNA polymerase I. <i>Biochemistry</i> , <b>1988</b> , 27, 546-53	3.2	33
4	Stability of acetylated and superguanidinated chymotrypsinogens. <i>Archives of Biochemistry and Biophysics</i> , <b>1982</b> , 216, 600-4	4.1	10
3	P53-independent restoration of p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9		1
2	HIF1 $\alpha$ inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells		1
1	The p53 pathway and apoptosis		1